Metabolism-targeting injections could pave the way for a new treatments, detection and prevention of bowel cancer ...

The seemingly inexorable rise in global obesity is being reflected in the sales of diabetes and weight-loss drugs, including ...

Slickly designed websites. Unbelievable markdowns. A simple online search for semaglutide, the active ingredient in Ozempic or Wegovy, can lead consumers down a rabbit hole of seemingly reputable ...

Novo Nordisk, the maker of Ozempic, reported that compounded versions of semaglutide, the main ingredient in Ozempic and ...

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.

Third quarter sales of Novo’s in-demand obesity drug totaled $2.5 billion, roughly 81% higher than the same period in 2023 and nearly doubling the total for Lilly’s Zepbound.

Novo Nordisk’s net profit of $3.94bn represents a 21% increase from Q3 2023. Net sales in the quarter jumped by the same ...

Japanese gynecological benign tumor market is thriving with cutting-edge diagnostic technologies and minimally invasive ...

UK health agencies will join forces with genetic sequencing company Oxford Nanopore Technologies to speed up screening of dangerous pathogens and give early warning of pandemic threats. The initiative ...

Endevica Bio has launched a new spin-off company, Abisati, to accelerate its obesity candidate into clinical trials.

Novo Nordisk has reported positive outcomes from part one of the ESSENCE trial of semaglutide 2.4 mg in treating MASH and ...